| 000 | 05826nam a22003975i 4500 | ||
|---|---|---|---|
| 999 |
_c88151 _d88151 _x1 |
||
| 001 | 88151 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230202105510.0 | ||
| 006 | a||||fo|||| 00| 0 | ||
| 007 | cr nn 008mamaa | ||
| 008 | 161101s2016 gw | s |||| 0|eng d | ||
| 020 | _a9783319435251 | ||
| 024 | 7 |
_a10.1007/978-3-319-43525-1 _2doi |
|
| 040 |
_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC |
||
| 050 | 4 |
_aRS199.5 _b2016 EB |
|
| 245 | 1 | 0 |
_aIntracellular Delivery III : _bMarket Entry Barriers of Nanomedicines _cedited by Ale Prokop, Volkmar Weissig |
| 264 | 1 |
_aCham _bSpringer International Publishing _c2016 |
|
| 300 |
_a1 recurso en línea (XIII, 453 páginas) _b81 ilustraciones, 65 ilustraciones en color |
||
| 336 |
_aTexto (visual) _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 490 | 1 |
_aFundamental Biomedical Technologies _x1559-7083 |
|
| 505 | 0 | _a1 Overview of present problems facing commercialization of nanomedicines, Ale Prokop and Volkmar Weissig -- 2 Precision medicine and site-specific drug delivery, Karel Petrák -- 3 Extracellular matrix degrading enzymes for nanocarrier-based anticancer therapy, Pablo Scodeller -- 4 Nanocarrier-based anticancer therapies with the focus on strategies for targeting the tumor microenvironment, Francisca Leonard and Biana Godin -- 5 New approach to minimize the MPS/RES uptake resulting a reduce toxic side effects of nanodrugs, Li Liu and Chien Ho -- 6 Authentic vascular and stromal structure in animal disease model for nanomedicine, Hiroshi Nishihara and Mitsunobu R Kano -- 7 Ligand-targeted nanocarriers with respect to their translation into the clinic, in particular in comparison with non-targeted nano-medicines, Roy Van der Meel, Laurens J.C. Vehmeijer, Robbert Jan Kok, Gert Storm, Ethlinn V.B. van Gaaland Gert Storm -- 8 Anti-angiogenic therapy by targeting the tumor vasculature with liposomes, Yu Sakurai and Hideyoshi Harashima -- 9 Accessing mitochondrial targets using nanocargos, Ru Wen, Afoma C. Umeano and Shanta Dhar -- 10 Redox-responsive nano-delivery systems for cancer therapy, Amit Singh, Thanh-Huyen Tran and Mansoor M. Amiji -- 11 Nano-emulsions for drug delivery and biomedical imaging, Nicolas Anton, François Hallouard, Mohammed F. Attia and Thierry F. Vandamme -- 12 The tumor microenvironment in nanoparticle delivery and the role of Imaging to navigate roadblocks and pathways, Dmitri Artemov and Zaver M Bhujwalla -- 13 Microscopic mass spectrometry for the precise design of drug delivery systems, Yasuhiro Matsumura and Masahiro Yasunaga -- 14 Pharmacokinetics and pharmacodynamics of nano-drug delivery systems, David Stepensky -- 15 Intracellular drug delivery in PBPK modelling though active and passive transport processes, Lars Kuepfer, Christoph Niederalt, Thomas Wendl, Jan-Frederil Schlender, Michael Block, Thomas Eissing, Donato Teutonic -- 16 Exploiting nanocarriers for combination cancer therapy, Yi Wen Kong, Erik C. Dreaden, Paula T. Hammond and Michael B. Yaffe -- 17 Commercialization of nanotechnology for medical applications, David W. Hobson -- Index | |
| 520 | _aA critical review is attempted to assess the status of nanomedicine entry onto the market. The emergence of new potential therapeutic entities such as DNA and RNA fragments requires that these new zdrugsy will need to be delivered in a cell-and organelle-specific manner. Although efforts have been made over the last 50 years or so to develop such delivery technology, no effective and above all clinically approved protocol for cell-specific drug delivery in humans exists as yet. Various particles, macromolecules, liposomes and most recently znanomaterialsy have been said to zshow promisey but none of these promises have so far been zreducedy to human clinical practice. The focus of this volume is on cancer indication since the majority of published research relates to this application; within that, we focus on solid tumors (solid malignancies). Our aim is critically to evaluate whether nanomaterials, both non-targeted and targeted to specific cells, could be of therapeutic benefit in clinical practice. The emphasis of this volume will be on pharmacokinetics (PK) and pharmacodynamics (PD) in animal and human studies. Apart from the case of exquisitely specific antibody-based drugs, the development of target-specific drug�carrier delivery systems has not yet been broadly successful at the clinical level. It can be argued that drugs generated using the conventional means of drug development (i.e., relying on facile biodistribution and activity after (preferably) oral administration) are not suitable for a target-specific delivery and would not benefit from such delivery even when a seemingly perfect delivery system is available. Therefore, successful development of site-selective drug delivery systems will need to include not only the development of suitable carriers, but also the development of drug entities that meet the required PK/PD profile | ||
| 988 | _aEBOOK, EBSPRINGER | ||
| 650 | 0 | 7 |
_aSistemas de liberación de fármacos _2embne _9667667 |
| 650 | 0 | 7 |
_aNanomedicina _2embne _9445593 |
| 700 |
_aProkop, Ale _eeditor literario _9101623 _0Local |
||
| 700 | 1 |
_aWeissig, Volkmar. _eeditor literario _9101624 _0Local |
|
| 830 | 0 |
_aFundamental Biomedical Technologies _x1559-7083 _0http://id.loc.gov/authorities/names/no2007024365 _9133437 |
|
| 856 | 4 | 0 | _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-3-319-43525-1zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 907 |
_a.b12981552 _b10-10-17 _c08-03-17 |
||
| 942 |
_2lcc _cLE |
||
| 945 |
_g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11603392 _z06-04-17 |
||
| 998 |
_b06/2020 _dz _eu _feng _ggw _h0 |
||